Physician profile
Robin R Deterding
NPI 1700961430
$107,922.77
in general payments reported to CMS, 2019-2025
7 companies · $13K in 2025
The $13K reported for 2025 was more than what 97% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $4,251 · 2021: $10K · 2022: $5,873 · 2023: $26K · 2024: $33K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $56K · Travel and Lodging: $9,182 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,759 · Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,698.00 |
| Travel and Lodging | $9,181.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,758.76 |
| Food and Beverage | $467.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $65,970.97 | 2019-2025 | Ofev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29,931.45 | 2021-2024 | Ofev |
| Evoendo, INC | $11,340.00 | 2023-2025 | |
| Roche Products Limited | $560.00 | 2022 | |
| Philips North America LLC | $120.35 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$421,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Deterding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.